United States
About Belite Bio, Inc.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for retinal degenerative eye diseases with significant unmet medical needs. Headquartered in San Diego, California, the company was founded in 2016 and operates as a subsidiary of Lin Bioscience International Ltd.
Key Product Candidates
- Tinlarebant (LBS-008) – An orally administered therapy currently in Phase 3 clinical trials for Stargardt disease type 1 and geographic atrophy. It aims to preserve retinal tissue health through early intervention.
- LBS-009 – A preclinical-stage anti-retinol-binding protein 4 oral therapy targeting liver diseases, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes, and gout.
Mission & Focus
Belite Bio is dedicated to advancing novel therapeutics that address critical gaps in retinal disease treatment, with a strong emphasis on improving patient outcomes through innovative research and clinical development.
